ASX:NEU Neuren Pharmaceuticals (NEU) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Neuren Pharmaceuticals Stock (ASX:NEU) 30 days 90 days 365 days Advanced Chart Get Neuren Pharmaceuticals alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume57,935 shsAverage VolumeN/AMarket Capitalization$1.68 billionP/E Ratio14.31Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewNeuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid, and in Phase 2 clinical trial for the treatment of Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.Read More… Receive NEU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neuren Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address NEU Stock News HeadlinesHealth Check: Neuren says more patients are staying the course as US Daybue sales liftMay 8 at 1:29 AM | msn.comThis $1.3b biotech is still run out of a spare bedroom in MelbourneApril 24, 2025 | afr.comTrump to redistribute trillions of dollars Seeing how the media and other analysts are covering Trump’s actions – it’s laughable. At least it would be laughable if it wasn’t putting so many Americans’ financial futures at severe risk… That’s why, with the 100-day mark of Trump’s second term just days away, it’s time to shine a light on what’s really going on, because if you move your money out of the wrong places and into the right ones before it’s too late… …you could be one of the few who profits from this imminent trillion-dollar reset.May 8, 2025 | Porter & Company (Ad)Dr Boreham’s Crucible: Drug-development unicorn Neuren banks on ‘cascade of long-term growth’April 14, 2025 | msn.comMonday's HotCopper Trends: Invictus exploration, Neuren's FDA tick | April 14, 2025April 14, 2025 | msn.comGuess which ASX 200 stock is surging 18% on big newsApril 14, 2025 | msn.comNeuren Pharma shares soar on progress for new drug trialApril 14, 2025 | msn.comWhy Core Lithium, Healius, Neuren, and Reject Shop shares are storming higher todayMarch 27, 2025 | msn.comSee More Headlines NEU Stock Analysis - Frequently Asked Questions How were Neuren Pharmaceuticals' earnings last quarter? Neuren Pharmaceuticals Limited (ASX:NEU) announced its earnings results on Wednesday, February, 27th. The company reported $0.03 EPS for the quarter. Neuren Pharmaceuticals had a trailing twelve-month return on equity of 55.28% and a net margin of 60.67%. What other stocks do shareholders of Neuren Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Neuren Pharmaceuticals investors own include Oxford Lane Capital (OXLC), Pilbara Minerals (PLS), Sunrise Energy Metals (SRL), Westpac Banking (WBC), FBR (FBR), Embark Early Education (EVO) and Dream Industrial Real Estate Investment Trust (DREUF). Company Calendar Last Earnings2/27/2019Today5/08/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryChemicals Current SymbolASX:NEU CIKN/A Webwww.neurenpharma.com Phone61 3 9092 0480FaxN/AEmployees2,060Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A$0.93 Trailing P/E Ratio14.31 Forward P/E RatioN/A P/E GrowthN/ANet Income$117.29 million Net Margins60.67% Pretax MarginN/A Return on Equity55.28% Return on Assets59.56% Debt Debt-to-Equity RatioN/A Current Ratio25.42 Quick Ratio31.54 Sales & Book Value Annual Sales$193.34 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow12.46 Book ValueA$1.72 per share Price / BookN/AMiscellaneous Outstanding Shares130,070,000Free FloatN/AMarket Cap$1.68 billion OptionableNot Optionable Beta2.13 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (ASX:NEU) was last updated on 5/8/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredIt may already be too late… A global energy shift is underway—and lithium is at the center of it. From electric vehicles to grid storage a...Huge Alerts | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredYour Wealth is Being Erased – Save It Before It’s Gone ForeverWhat If America's Gold Reserves Are a Lie? For decades, the U.S. government has claimed to have thousands o...Hamilton Gold Group | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuren Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Neuren Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.